Allitinib

DB18840ExperimentalSmall molecule

Allitinib is under investigation in clinical trial NCT04671303 (To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₄H₁₈ClFN₄O₂ · 448.88 g/mol (avg)
Also known as: 2-propenamide, n-(4-((3-chloro-4-((3-fluorophenyl)methoxy)phenyl)amino)-6-quinazolinyl)- · N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)acrylamide · N-(4-((3-chloro-4-((3-fluorophenyl)methoxy)phenyl)amino)-6-quinazolinyl)-2-propenamide
Code names: ALS 1306 · AST 1306

Resolves to

Compound

UNIICX0M5RO7CYCAS897383-62-9ChEMBLCHEMBL1947204ChEBI91467

Structure

InChIKeyMVZGYPSXNDCANY-UHFFFAOYSA-NSMILESFC1=CC=CC(COC2=CC=C(NC3=NC=NC4=CC=C(NC(=O)C=C)C=C34)C=C2Cl)=C1

Targets

P04626ERBB2P00533EGFR

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Allitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account